key: cord-0999992-lfpdrg3o authors: Zuo, Tao; Zhang, Fen; Lui, Grace C.Y.; Yeoh, Yun Kit; Li, Amy Y.L.; Zhan, Hui; Wan, Yating; Chung, Arthur; Cheung, Chun Peng; Chen, Nan; Lai, Christopher K.C.; Chen, Zigui; Tso, Eugene Y.K.; Fung, Kitty S.C.; Chan, Veronica; Ling, Lowell; Joynt, Gavin; Hui, David S.C.; Chan, Francis K.L.; Chan, Paul K.S.; Ng, Siew C. title: Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization date: 2020-05-20 journal: Gastroenterology DOI: 10.1053/j.gastro.2020.05.048 sha: 237611ecafe34f49d793f86993584457f0b882a5 doc_id: 999992 cord_uid: lfpdrg3o Abstract BACKGROUD & AIMS: Although SARS-CoV-2 infects gastrointestinal tissues, little is known about the roles of gut commensal microbes in susceptibility to and severity of infection. We investigated changes in fecal microbiomes of patients with SARS-CoV-2 infection during hospitalization and associations with severity and fecal shedding of virus. METHODS We performed shotgun metagenomic sequencing analyses of fecal samples from 15 patients with COVID-19 in Hong Kong, from February 5 through March 17, 2020. Fecal samples were collected 2 or 3 times per week from time of hospitalization until discharge; disease was categorized as mild (no radiographic evidence of pneumonia), moderate (pneumonia was present), severe (respiratory rate ≥30/min, or oxygen saturation ≤93% when breathing ambient air), or critical (respiratory failure requiring mechanical ventilation, shock, or organ failure requiring intensive care). We compared microbiome data with those from 6 subjects with community-acquired pneumonia and 15 healthy individuals (controls). We assessed gut microbiome profiles in association with disease severity and changes in fecal shedding of SARS-CoV-2. RESULTS Patients with COVID-19 had significant alterations in fecal microbiomes compared with controls, characterized by enrichment of opportunistic pathogens and depletion of beneficial commensals, at time of hospitalization and at all timepoints during hospitalization. Depleted symbionts and gut dysbiosis persisted even after clearance of SARS-CoV-2 (determined from throat swabs) and resolution of respiratory symptoms. The baseline abundance of Coprobacillus, Clostridium ramosum, and Clostridium hathewayi correlated with COVID-19 severity; there was an inverse correlation between abundance of Faecalibacterium prausnitzii (an anti-inflammatory bacterium) and disease severity. Over the course of hospitalization, Bacteroides dorei, Bacteroides thetaiotaomicron, Bacteroides massiliensis, and Bacteroides ovatus, which downregulate expression of ACE2 in murine gut, correlated inversely with SARS-CoV-2 load in fecal samples from patients. CONCLUSIONS In a pilot study of 15 patients with COVID-19, we found persistent alterations in the fecal microbiome during the time of hospitalization, compared with controls. Fecal microbiota alterations were associated with fecal levels of SARS-CoV-2 and COVID-19 severity. Strategies to alter the intestinal microbiota might reduce disease severity. COVID-19 is a respiratory illness caused by a novel coronavirus (SARS-CoV-2) and over 3.3 million people worldwide have been infected as of May 1, 2020. Although most cases of COVID-19 are mild, disease can be severe resulting in hospitalization, respiratory failure, or death 1 . Early reports from Wuhan showed that 2-10% of COVID-19 patients had gastrointestinal (GI) symptoms including diarrhea but a recent meta-analysis reported that up to 20% had GI symptoms [2] [3] [4] [5] . Studies have detected SARS-CoV-2 virus in anal swabs and stool samples in almost 50% of COVID-19 patients, suggesting that the digestive tract might be an extra-pulmonary site for virus replication and activity 6, 7 . Moreover, fecal calprotectin were found to be elevated in COVID-19 patients with diarrhea 8 , an indicator of inflammatory responses in the gut. SARS-CoV-2 uses the angiotensin converting enzyme 2 (ACE2) receptor to enter the host and this receptor is highly expressed in both the respiratory and gastrointestinal tract 9, 10, 11 . ACE2 is important in controlling intestinal inflammation and gut microbial ecology 12 . With trillions of diverse bacteria dwelling in our gut, the gut microbiome has a myriad of effects on gene regulation of immune response and metabolism. The commensal microbiota ecosystem in the gut is dynamic and can be regulated by invading viruses to facilitate a stimulatory or suppressive response 13 . Studies have shown that respiratory viral infections may be associated with altered gut microbiome, which predispose patients to secondary bacterial infections 14, 15 . Recent meta-transcriptome sequencing of bronchoalveolar lavage fluid showed that the microbiota in SARS-CoV-2 infected patients was dominated by pathogens or oral and upper respiratory commensal bacteria 16 . In addition, co-morbidities commonly associated with severe COVID-19 are known to be associated with alterations in bacteria taxa from the phyla Bacteroidetes and Firmicutes [17] [18] [19] [20] , which were reported to regulate ACE2 expression in rodents 21 . There is an urgent need to understand host microbial perturbations that underlies SARS-CoV-2 infection, which may impact response to infection and efficacy of various future immune interventions, such as vaccines 22 . In this pilot study, we hypothesize that the intestinal microbiota is altered in SARS-CoV-2 infection and is associated with susceptibility to severe disease. We prospectively included 15 hospitalised COVID-19 patients admitted between February 16, 2020 and March 2, 2020 in Hong Kong, China, followed from hospital admission until discharge. Through the application of deep shotgun metagenomics, we investigated longitudinal changes of the gut microbiome in COVID-19. This prospective study involved 15 COVID-19 patients hospitalized with laboratoryconfirmed SARS-CoV-2 infection, six patients hospitalized with community acquired pneumonia (pneumonia controls) and fifteen healthy individuals (healthy controls) ( Table 1 SARS-CoV-2 viral loads in stool were measured using real-time reverse-transcriptasepolymerase chain-reaction (RT-PCR) assay. Viral RNA from stool samples was extracted using QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). 0.1g of stool was suspended in 1 mL of viral transport medium (in 1:10 dilution) and centrifuged for 20 min at 4000g. A 140-µL aliquot of the filtrate was used as starting material following the manufacturer's protocol. SARS-CoV-2 RNA was quantified using real-time reverse-transcriptasepolymerase-chain-reaction (RT-PCR). The primer-probe set N1 (2019-nCoV_N1-F: 5'-GAC CCC AAA ATC AGC GAA AT-3', 2019-nCoV_N1-R: 5'-TCT GGT TAC TGC CAG TTG AAT CTG-3' and 2019-nCoV_N1-P: 5'-FAM-ACC CCG CAT TAC GTT TGG TGG ACC-BHQ1-3 Approximately 0.1g fecal sample was prewashed with 1 ml ddH 2 O and pelleted by centrifugation at 13,000×g for 1 min. The fecal DNA was subsequently extracted from the pellet using Maxwell® RSC PureFood GMO and Authentication Kit (Promega, Madison, Wisconsin) following manufacturer's instructions. Briefly, fecal pellet was added 1ml of CTAB buffer and vortexed for 30 seconds, then heating sample at 95°C for 5 minutes. After that, the samples were vortexed thoroughly with beads at maximum speed for 15 min. Then 40µl of proteinase K and 20µl of RNase A was added into sample and the mixture was Incubated at 70°C for 10 minutes. The supernatant was then obtained by centrifuging at 13,000×g for 5 min and was added in Maxwell® RSC machine for DNA extraction. Extracted DNA was subject DNA libraries construction, completed through the processes of end repairing, adding A to tails, purification and PCR amplification, using Nextera DNA Flex Library Preparation kit (Illumina). Libraries were subsequently sequenced on our in-house sequencer Illumina NextSeq 550 (150bp paired-end) at Center for microbiota research, The Chinese University of Hong Kong. Raw sequence reads were filtered and quality-trimmed using Trimmomatic v0.36 24 as follows: 1) Trimming low quality base (quality score < 20); 2) Removing reads shorter than 50bp; 3) removing sequencing adapters. Contaminating human reads were filtering using Kneaddata (Reference database: GRCh38 p12) with default parameters. Profiling of bacterial communities was performed using MetaPhlAn2 (V2.9) by mapping reads to clade-specific markers 25 . Relative data from MetaPhlAn2 were imported into R v3.5.1. Non-metric Multi-dimensional Scaling (NMDS) analyses were performed on all baseline fecal microbiomes between groups, and serial fecal microbiomes in each COVID-19 case during the disease course, based on Bray-Curtis dissimilarities using vegan package (v2. . Differential bacterial taxa between COVID-19 patients (with or without antibiotics treatment at inclusion), communityacquired pneumonia patients, and healthy controls were identified using Multivariate Association with Linear Models (MaAsLin) 26 . Spearman correlation analyses were conducted to associate baseline microbiome profiles of 7 antibiotics naïve patients at baseline with COVID-19 severity, and to associate longitudinal fecal SARS-CoV-2 loads with timepointmatched bacterial profiles across all 15 COVID-19 patients, while adjusting for confounding factors. Metagenomics Sequencing dataset was deposited to the NCBI Sequence Read Archive under BioProject accession number PRJNA624223. Among the fifteen COVID-19 patients, 7 were antibiotics-naïve [COVID-19(abx-)] and 8 received empirical antibiotics [COVID-19(abx+)] at baseline (defined as date of the first stool collection after hospitalization). The median age of COVID-19 patients, pneumonia controls and healthy controls were 55, 50 and 48 years old, respectively. 40% and 100% of COVID-19 patients and pneumonia controls, respectively, had underlying co-morbidities (Table 1; supplementary table 1 Among all host factors, COVID-19 infection showed the largest effect size in affecting the gut microbiome (PERMANOVA test, R 2 =0.066, p=0.002, Figure 2a) , followed by hyperlipidemia, pneumonia, and antibiotics, while age and gender showed no significant effects on gut microbiome alterations (Figure 2a) . At the whole microbiome community level, healthy subjects' fecal microbiome clustered together whereas that of COVID-19 (Abx-) patients clustered separately (PERMANOVA test, p=0.001) and were more heterogeneous (Figure 2b ). Antibiotic treatment in COVID-19 patients was associated with a more heterogenous microbiome configuration and accompanied by further shift of the gut microbiome away from a healthy microbiome (Figure 2b) . We next explored whether recovery from SAR-CoV-2 infection was associated with restoration of gut microbiome to a community level similar to that of healthy individuals. Overall, the gut microbiome of all COVID-19 patients remained stable but were markedly disparate from that of healthy controls, both during the disease course and after clearance of SARS-CoV-2 (Figure 2c) . While five COVID-19 patients' microbiome (CoV1, 4, 7, 11, 15) showed closer proximity to healthy microbiomes over time, patients CoV3, 5, 8, 10, and 12 became more disparate from healthy microbiomes over time (Supplementary Figure 7) . At the last follow-up, the gut microbiome of these ten patients remained substantially different from that of healthy controls, despite clearance of SARS-CoV-2 infection as defined by negative SARS-CoV-2 tests on nasopharyngeal swab or deep throat saliva (Figure 2c, Supplementary Figure7 ). Of note, patient CoV4 was discharged on Day 5 but his gut microbiome on Day 22 were persistently different from that of healthy individuals. To understand whether baseline gut microbiome impacts the severity of COVID-19, we assessed association between baseline fecal microbiome and COVID-19 severity (mild, moderate, severe, or critical) in seven antibiotic-naïve COVID-19 cases. A total of 23 bacterial taxa were found to be significantly associated with COVID-19 disease severity, most of which (15 out of 23) were from the Firmicutes phylum (Table 3) Three bacterial members from the Firmicutes phylum, the genus Coprobacillus, the species Clostridium ramosum and Clostridium hathewayi, were the top bacteria positively associated with COVID-19 disease severity (Spearman correlation coefficient Rho>0.9, p<0.01, Table 3 ). Both Clostridium ramosum and Clostridium hathewayi have been associated with human infection and bacteremia 27, 29 . Importantly, Coprobacillus bacterium has been shown to strongly up-regulate colonic expression of ACE2 in the murine gut 21 . In contrast, two beneficial species Alistipes onderdonkii and Faecalibacterium prausnitzii were top bacterial species to show a negative correlation with COVID-19 severity ( Table 3) . Alistipes species are indole positive, involved in the serotonin precursor tryptophan metabolism and in maintaining gut immune homeostasis 30, 31 , while Faecalibacterium prausnitzii has antiinflammatory properties 32 . Although we cannot assign a causative or preventive role of these bacteria in disease pathogenesis or severity, our data underscore a potential role for bacteria in determining response to SARS-CoV-2 infection and intensity of the infection in the host. Eleven of the 15 patients had SARS-CoV-2 nucleic acid detected in feces at hospitalization (median 3.86×10 3 copies per mL inoculum, as determined by RT-PCR) and five of them cleared the SARS-CoV-2 virus over time (Figure 3a) . We investigated whether gut bacteria were associated with fecal SARS-CoV-2 load over the course of hospitalization. A total of 14 bacterial species were identified to be significantly associated with fecal viral load of SARS-CoV-2 across all fecal samples (Figure 3b) . Among them, 6 species were from the Erysipelotrichaceae may play a role in augmenting SARS-CoV-2 infection in the host gut. We showed for the first time that the gut microbiome was disturbed in patients with COVID-19. The alterations, observed even in COVID-19 patients naïve to antibiotic therapy, were characterized by enrichment of opportunistic pathogens and depletion of beneficial commensals (Figure 4) . Recently, a study provided direct evidence that SARS-CoV-2 can bind to human ACE2 as host entry point 9 . ACE2 is highly expressed in the intestine especially in colonocytes of healthy subjects and in patients with inflammatory bowel disease 10 , and can regulate amino acid transport, microbial ecology and inflammation in the gut 12 (Figure 4) . Among them, Bacteroides dorei has been reported to suppress colonic ACE2 expression 21 and to calibrate host immune response 39, 40 . The highest SARS-CoV-2 mortality and morbidity has been reported in older patients and in those with underlying chronic diseases that are associated with inflammation such as hypertension, obesity, diabetes mellitus and coronary artery disease [41] [42] [43] . Interestingly, these subjects were also reported to have a lower abundance of Bacteroides species than healthy individuals [17] [18] [19] [20] . These findings altogether suggest that an individual's gut microbiome configuration may affect the subject's susceptibility and response to SARS-CoV-2 infection. Cytokine profile associated with hyperinflammation state in severe COVID-19 has been The use of empirical antibiotics (which was common in the initial outbreak of SARS-CoV-2 when secondary bacterial infection was a concern) led to further loss of salutary symbionts and exacerbation of gut dysbiosis in COVID-19 patients and our data support avoidance of unnecessary antibiotics use in the treatment of viral pneumonitis, as antibiotics can eliminate beneficial bacteria and weaken the gut barrier 45 . In addition, antibiotics-driven gut microbiome perturbation can alter immunity to vaccines in humans 46 . Improving efficacy of future immune interventions such as vaccines, through modulating the gut microbiome, in combating COVID-19 should be considered. One approach for promoting a healthy microbiome may include measures to enhance intestinal butyrate production through the promotion of microbial interactions by dietary changes, and reduction of pro-inflammatory states. In conclusion, our study provides evidence of prolonged gut microbiome dysbiosis in COVID-19 and its association with fecal SARS-CoV-2 virus shedding and disease severity. These data highlight a new concept that novel and targeted approach of modulation of the gut microbiota may represent a therapeutic avenue for COVID-19 and its co-morbidities. Table 3 . Gut bacteria correlated with COVID-19 severity Co-morbidities 6 (40%) 6 (100%) 0 (0%) Travel to cities of Hubei province 1 (7%) 0 (0%) 0 (0%) Contact with person with COVID19 5 (33%) 0 (0%) 0 (0%) Have family cluster outbreak 4 (27%) 0 (0%) 0 (0%) What you need to know BACKGROUD AND CONTEXT: SARS-CoV-2 infects gastrointestinal tissues. The authors investigated changes in fecal microbiomes of patients with SARS-CoV-2 infection during hospitalization and associations with severity and fecal shedding of virus. Fecal microbiomes from patients with COVID-19 had depletion of symbionts and enrichment of opportunistic pathogens, which persisted after clearance of SARS-CoV-2. Baseline microbiome composition associated with COVID-19 severity. Multiple species from the Bacteroidetes phylum correlated inversely with fecal shedding of SARS-CoV-2. This was a pilot exploratory study of 15 patients with COVID-19; further studies are needed of alterations in intestinal microbiomes of these patients over time. These findings indicate the prolonged effect of SARS-CoV-2 infection on the gut microbiomes of patients with COVID-19. Strategies to alter the gut microbiome might be developed to manage gastrointestinal effects of the virus in these patients. Lay Summary: COVID-19 patients have altered gut microbiome with depletion of symbionts and enrichment of opportunistic pathogens, which correlate with disease severity. Such gut microbiome dysbiosis could persist even after clearance of SARS-CoV-2. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy Clinical features of patients infected with 2019 novel coronavirus in Wuhan Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis Virological assessment of hospitalized patients with COVID-2019 Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding Faecal calprotectin indicates intestinal inflammation in COVID-19 Structural basis of receptor recognition by SARS-CoV-2 ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism Evidence for gastrointestinal infection of SARS-CoV-2 ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation The commensal microbiota and viral infection: a comprehensive review Respiratory viral infection-induced Microbiome alterations and secondary bacterial pneumonia Influenza A virus infection impacts systemic microbiota dynamics and causes quantitative enteric dysbiosis Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients An obesity-associated gut microbiome with increased capacity for energy harvest Analysis of gut microbiota in coronary artery disease patients: a possible link between gut microbiota and coronary artery disease Gut dysbiosis is linked to hypertension Human gut microbes associated with obesity Mining the human gut microbiota for immunomodulatory organisms Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles Clinical characteristics of imported cases of COVID-19 in Jiangsu province: a multicenter descriptive study Trimmomatic: a flexible trimmer for Illumina sequence data Metagenomic microbial community profiling using unique clade-specific marker genes Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment Human infection caused by Clostridium hathewayi A Literature Review on Dental Caries Vaccine-A Prevention Strategy Clostridium ramosum bacteremia: case report and literature review Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism Importance of the microbiota in early life and influence on future health. The Gut-Brain Axis Faecalibacterium prausnitzii and human intestinal health Insights into the role of Erysipelotrichaceae in the human host Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation Influenza virus affects intestinal microbiota and secondary salmonella infection in the gut through type I interferons Respiratory disease following viral lung infection alters the murine gut microbiota Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness Actinomyces viscosus causing disseminated disease in a patient on methotrexate Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans Bacteroides vulgatus and Bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Commentary: COVID-19 in Patients with Diabetes Mechanisms by which the gut microbiota influences cytokine production and modulates host inflammatory responses Antibiotic treatment affects intestinal permeability and gut microbial composition in Wistar rats dependent on antibiotic class Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans Author names in bold designate shared co-first authorship